Literature DB >> 14750575

The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2).

Wim H Van Brakel1, Alison M Anderson, Stephen G Withington, Richard P Croft, Peter G Nicholls, Jan H Richardus, W Cairns S Smith.   

Abstract

This study was designed to investigate whether leprosy patients diagnosed with mild sensory impairment have a better prognosis when treated with steroids than similarly impaired patients treated with placebo. A multi-centre, randomized, double-blind, placebo-controlled trial was conducted in Nepal and Bangladesh. Patients were eligible if they had a confirmed leprosy diagnosis, were between 15 and 50 years old, had mild sensory impairment of the ulnar or posterior tibial nerve of less than 6 months duration and did not require steroids for other reasons. 'Mild impairment' was defined as 'impaired on the Semmes-Weinstein monofilament test, but testing normal on the ballpen sensory test'. Subjects were randomized to either prednisolone treatment starting at 40 mg per day, tapering over 4 months, or placebo. Nerve function was monitored monthly. Any patient who deteriorated was taken out of the trial and was put on full-dose steroid treatment. Outcome assessment was done at 4, 6, 9 and 12 months from the start of the treatment. Outcome measures were the proportion of patients needing full-dose prednisolone and the Semmes-Weinstein sum scores. Each patient contributed only one nerve to the analysis. Seventy-five patients had nerves eligible for analysis, of whom 41 (55%) and 34 (45%) were allocated to the prednisolone and placebo arms, respectively. At 4 months, three patients in the prednisolone arm (7%) and six in the placebo arm (18%) had an outcome event requiring full dose steroids. At 12 months, these proportions had almost reversed, 11 (27%) and 6 (18%) in the treatment and placebo arms, respectively. In the latter group, 75% had recovered spontaneously after 12 months. Prednisolone treatment of sensory impairment of the ulnar and posterior tibial nerves detectable with the monofilament test, but not with the ballpen test, did not improve the long-term outcome in terms of recovery of touch sensibility, not did it reduce the risk of leprosy reactions or nerve function impairment beyond the initial 4-month treatment phase. Two unexpected main findings were the strong tendency of mild sensory impairment to recover spontaneously and the fact that patients with mild sensory impairment without any other signs or symptoms of reaction or nerve function impairment are relatively rare.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14750575

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  11 in total

Review 1.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

2.  Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).

Authors:  W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus
Journal:  BMJ       Date:  2004-05-24

3.  A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment.

Authors:  Stephen L Walker; Peter G Nicholls; Sushmita Dhakal; Rachel A Hawksworth; Murdo Macdonald; Kishori Mahat; Shudan Ruchal; Sushma Hamal; Deanna A Hagge; Kapil D Neupane; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2011-04-12

4.  AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.

Authors:  Diana N J Lockwood; Joydeepa Darlong; Pitchaimani Govindharaj; Royce Kurian; Pamidipani Sundarrao; Annamma S John
Journal:  PLoS Negl Trop Dis       Date:  2017-03-30

5.  A Macrophage Response to Mycobacterium leprae Phenolic Glycolipid Initiates Nerve Damage in Leprosy.

Authors:  Cressida A Madigan; C J Cambier; Kindra M Kelly-Scumpia; Philip O Scumpia; Tan-Yun Cheng; Joseph Zailaa; Barry R Bloom; D Branch Moody; Stephen T Smale; Alvaro Sagasti; Robert L Modlin; Lalita Ramakrishnan
Journal:  Cell       Date:  2017-08-24       Impact factor: 41.582

6.  Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols.

Authors:  Inge Wagenaar; Wim Brandsma; Erik Post; Wim van Brakel; Diana Lockwood; Peter Nicholls; Paul Saunderson; Cairns Smith; Einar Wilder-Smith; Jan Hendrik Richardus
Journal:  BMC Neurol       Date:  2012-12-18       Impact factor: 2.474

Review 7.  Cost-effectiveness of interventions to prevent disability in leprosy: a systematic review.

Authors:  Natasja H J van Veen; Paul McNamee; Jan Hendrik Richardus; W Cairns S Smith
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

8.  The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.

Authors:  Stephen L Walker; Eglantine Lebas; Shimelis N Doni; Diana N J Lockwood; Saba M Lambert
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

9.  A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.

Authors:  Saba M Lambert; Digafe T Alembo; Shimelis D Nigusse; Lawrence K Yamuah; Stephen L Walker; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05

10.  Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

Authors:  Inge Wagenaar; Erik Post; Wim Brandsma; Bob Bowers; Khorshed Alam; Vanaja Shetty; Vivek Pai; Sajid Husain; Cita Rosita Sigit Prakoeswa; Linda Astari; Deanna Hagge; Mahesh Shah; Kapil Neupane; Krishna Bahadur Tamang; Peter Nicholls; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2017-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.